Table 3.
Impact of Supplementing PSA Cutoffs With PCA3 Scores in Probability of Detecting Any Cancer and HG Cancer
| PCA3 Score | Initial Biopsy PSA (ng/mL) |
Repeat Biopsy PSA (ng/mL) |
||||||
|---|---|---|---|---|---|---|---|---|
| < 4 | 4 to 10 | > 10 | Total | < 4 | 4 to 10 | > 10 | Total | |
| PCA3 score < 20 | ||||||||
| Any cancer | 31 | 44 | 67 | 41 | 15 | 18 | 22 | 19 |
| Any cancer (plus PCA3) | 17 | 26 | 49 | 25 | 7 | 10 | 11 | 9 |
| Any cancer (observed) | 15 | 26 | 53 | 24 | 9 | 13 | 12 | 12 |
| HG cancer | 11 | 20 | 53 | 19 | 4 | 6 | 11 | 7 |
| HG cancer (plus PCA3) | 6 | 12 | 39 | 12 | 2 | 3 | 6 | 4 |
| HG cancer (observed) | 5 | 15 | 41 | 13 | 0 | 3 | 6 | 2 |
| PCA3 score 20 to 60 | ||||||||
| Any cancer | 34 | 52 | 68 | 49 | 15 | 18 | 31 | 21 |
| Any cancer (plus PCA3) | 39 | 56 | 69 | 53 | 16 | 19 | 33 | 23 |
| Any cancer (observed) | 35 | 56 | 59 | 50 | 21 | 22 | 21 | 22 |
| HG cancer | 13 | 29 | 54 | 28 | 3 | 7 | 16 | 9 |
| HG cancer (plus PCA3) | 14 | 29 | 53 | 28 | 3 | 6 | 16 | 9 |
| HG cancer (observed) | 15 | 28 | 55 | 28 | 0 | 7 | 15 | 8 |
| PCA3 score > 60 | ||||||||
| Any cancer | 41 | 55 | 85 | 56 | 32 | 24 | 41 | 30 |
| Any cancer (plus PCA3) | 65 | 77 | 94 | 76 | 47 | 42 | 63 | 49 |
| Any cancer (observed) | 65 | 82 | 100 | 80 | 33 | 52 | 50 | 50 |
| HG cancer | 18 | 30 | 77 | 33 | 10 | 8 | 23 | 13 |
| HG cancer (plus PCA3) | 27 | 44 | 87 | 45 | 14 | 14 | 34 | 21 |
| HG cancer (observed) | 23 | 42 | 100 | 45 | 0 | 21 | 30 | 23 |
| Total (any cancer) | 34 | 50 | 72 | 47 | 16 | 19 | 30 | 22 |
| Total (HG cancer) | 13 | 26 | 60 | 26 | 4 | 7 | 16 | 9 |
NOTE. “Any cancer” denotes the probability of detection of prostate cancer based on a multivariable logistic regression risk prediction model that includes prostate-specific antigen (PSA), first-degree family history, digital rectal examination, prior biopsy, age, and prostate size. “High-grade (HG) cancer” denotes the probability of detection of high-grade prostate cancer based on a multivariable logistic regression risk prediction model that includes PSA, digital rectal examination, prior biopsy, age, African American race, prostate size, and free PSA. “Plus prostate cancer antigen 2 (plus PCA3)” denotes the probability of detection of prostate cancer when a risk prediction model is supplemented with PCA3 score. “Observed” denotes actual cancer or high-grade cancer detection in the cohort.